ABOUT CROHN'S

Crohn’s Disease affects about 3.2 per 1000 in North America and Europe and cases are rapidly growing in Asia, and parts of South America. As a consequence, the increasing global burden regarding healthcare costs is significant. In addition, the disease substantially impacts the quality of life of those who are afflicted. Read more here about Crohn's and how we hope to help cure it.

What is Crohn's Disease?

 

Crohn’s was first described by Giovanni Battista Morgagni in the 18th century. Yet we still don’t know, with certainty, what causes it. It can be managed, but there is presently no cure. Crohn's is a debilitating disease that causes inflammation anywhere along the digestive tract, from the mouth to the anus.

Typical Crohn's Symptoms:

  • Diarrhea or Constipation

  • Anemia

  • Abdominal pain

  • Weight loss

  • Fatigue

  • Blood in stool

  • Mucus in stool

More About Crohn's Disease

80% of those diagnosed with Crohn's Disease require major surgery.

It can occur at any age but usually strikes teenagers and young adults at the cusp of adulthood, between the ages of 12 to 30.

Patients can have long periods of remission, where they have no symptoms or only very mild symptoms, but then see their symptoms return in a flare. 

Some will have just a few symptoms their entire lives.

Others will have chronic and severe cases where they experience never ending symptoms and pain.

Some have "Silent Crohn's" where there are no overt symptoms, but inflammation informed by elevated CRP levels and endoscopies show active disease. 37% will end up having surgery within two years.

Genes, microbes, and environment play a role.

Crohn's is growing in prevalence worldwide.

In 1999, IBD affected 0.9% of the population.

Today it affects 3.2 per 1000 in North America and Europe.

4 million worldwide.

In the last 15 years cases have grown 60% in the under 18 age group.

Under 10 is the fastest growing group. 

Canada has seen a 50% increase in pediatric cases in the last 10 years. 

Cost depends on severity.

The top 25% of total costs averaged $60,582 per year.

Cost of patients in the top 2% averaged more than $300,000 per year. 

For mild to moderate cases the estimated direct medical costs have been estimated to be between $22,987 and  $18,022-18,932 per patient with CD per year in the United States vs. $6956 for healthy controls.

And more than twice the out of pocket costs: $2213 vs $979, in Europe: € 2898-6960 

Combining prevalence rates, the total economic burden of CD was $10.9-15.5 billion in the United States and €2.1-16.7 billion in Europe.

Hospitalizations accounted for 53-66% of direct medical costs, with an average cost-per-hospitalization of $37,459 in the United States. 

Compared with adults without IBD, those with IBD are more likely to have certain chronic health conditions that include:

  • Cardiovascular disease (CVD)

  • Respiratory disease

  • Cancer

  • Arthritis

  • Kidney disease

  • Liver disease

  • Neurological conditions like Parkinson’s 

Statistically, Crohn’s Disease research monies trail many other conditions. In 2018 $69 million was spent on Crohn’s research but $3,000 million for HIV, $83 million for ALS and $152 million for Osteoporosis. Propel a Cure believes this must change, and so we are funding cutting-edge research, using the latest technologies that will determine the cause, leading to a CURE.

Please join us to help make it happen!

Propel-a-Cure_Logo_2020_03a.png

925-269-4116  |  info@propelacure.org